Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:17:14.849Z.
Calculation as of: 2026-10-06T19:17:14.849Z.
Quote observation: 2026-10-06T19:15:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 764f42141b21779aba3712b54ee9373bee46ed3fd4a49ef41b5b57d04fae8ed9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$236.76M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$236.09M
Price/OCF Ratio
5.68
TTM Avg
7.79
3Y Avg
7.79
5Y Avg
7.79
Market Cap
$240.61M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$235.69M
Price/OCF Ratio
19.89
TTM Avg
15.29
3Y Avg
13.49
5Y Avg
14.36
Market Cap
$241.94M
Price/OCF Ratio
N/A
TTM Avg
252.82
3Y Avg
252.82
5Y Avg
155.13
Market Cap
$232.03M
Price/OCF Ratio
N/A
TTM Avg
6.47
3Y Avg
15.02
5Y Avg
16.17
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Invivyd, Inc. (IVVD) | $237.13M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $236.76M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.09M | 5.68 | 7.79 | 7.79 | 7.79 |
| High Tide Inc. (HITI)vs › | $238.57M | 13.34 | 11.46 | 10.55 | 21.56 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.61M | N/A | N/A | N/A | N/A |
| Utah Medical Products, Inc. (UTMD)vs › | $235.69M | 19.89 | 15.29 | 13.49 | 14.36 |
| InflaRx N.V. (IFRX)vs › | $234.93M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | N/A | 252.82 | 252.82 | 155.13 |
| SIGA Technologies, Inc. (SIGA)vs › | $232.03M | N/A | 6.47 | 15.02 | 16.17 |
| Q32 Bio Inc. (QTTB)vs › | $242.58M | N/A | 8.05 | 8.05 | 8.05 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
